Drug Search Results
More Filters [+]

Terbutaline

Alternative Names: terbutaline, terbutalin, bricanyl, bricasol, brethaire, brethine
Latest Update: 2023-11-21
Latest Update Note: Clinical Trial Update

Product Description

Terbutaline is a selective beta 2 agonist used predominantly in the treatment of asthma. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/7096576/)

Mechanisms of Action: ADR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Australia | Austria | Bangladesh | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Singapore | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Terbutaline

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TBS02

P3

Recruiting

Asthma

2025-12-01

Recent News Events